tbuckley/cabot-search huggingface dataset:
Abstract 19518: Revascularization Based-Strategy and Subsequent Outcomes Among Patients With Spontaneous Coronary Artery Dissection Presenting as ST-Elevation Myocardial Infarction: A Multicenter US Registry
Authors: Angie S Lobo, Stephanie M Cantu, Ross F Garberich, Yasuhiko Kubota, Dawn Witt, Gretchen Benson, Timothy D Henry, Scott W Sharkey, Elizabeth Z Grey
Journal: Circulation (2017)

Introduction: Conservative management has been proposed for patients with spontaneous coronary artery dissection (SCAD); however, this strategy is not necessarily appropriate in those with acute ST...
Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML
Authors: Robert Puckrin, Eshetu G Atenafu, Jaime Claudio, Steven M Chan, Vikas Gupta, Dawn Maze, Caroline J McNamara, Mark D. Minden, Andre Schuh, Tracy Murphy, Hassan Sibai, Karen W.L. Yee, Tracy L. Stockley, Suzanne Kamel-Reid, Aaron D Schimmer
Journal: Blood (2018)
Abstract P157: Sex Disparities in High Intensity Statin Use Following Myocardial Infarction
Authors: Rikki M Tanner, Robert Rosenson, Keri Monda, Monika Safford, Ben Taylor, Yu Ling Dai, Hong Zhao, Paul Muntner, Vera Bittner
Journal: Circulation (2017)

Background: High intensity statins have been shown to lower the risk of major cardiovascular events after an index myocardial infarction (MI). Studies have shown that women are less likely than men to receive cardiovascular risk reduction therapies but little is known about sex differences in high intensity statin use following hospital discharge for MI. Methods: We compared high intensity statin use following hospital discharge for MI in 2014 between men and women 19 to 64 years with commercial health insurance in the Marketscan database (n=7,089 men and 2,318 women) and Medicare beneficiaries ≥66 years (n=20,202 men and n=18,937 women). Patients were included if they filled a statin of any intensity within 30 days following hospital discharge. Statin fills were identified through pharmacy claims and high intensity statins included atorvastatin 40 or 80 mg and rosuvastatin 20 or 40 mg. Results: Among patients not taking statins prior to having an MI (n=6,303 in Marketscan and n=17,763 in Medicare), 69.4% of men and 62.4% of women (p-value &lt;0.001) in the Marketscan database and 55.2% of men and 48.1% of women (p-value &lt;0.001) with health insurance through Medicare initiated treatment with a high intensity statin. Among patients taking low or moderate intensity statins prior to having an MI (n=2,234 in Marketscan and n=16,818 in Medicare), 58.0% of men and 49.2% of women (p-value &lt;0.001) in the Marketscan database and 38.2% of men and 31.7% of women (p-value &lt;0.001) in Medicare titrated to a high intensity statin within 30 days of hospital discharge. After multivariable adjustment, women were less likely to initiate treatment with a high intensity statin (relative risk: 0.92; 95% CI 0.88-0.96 in Marketscan and 0.92; 95% CI 0.90-0.95 in Medicare) or titrate from low/moderate to high intensity statin (relative risk: 0.89 95% CI 0.81-0.95 in Marketscan and 0.89; 95% CI 0.86-0.93 in Medicare). Among those taking a high intensity statin prior to their MI (n=870 in Marketscan and n=4,558 in Medicare), 92.0% and 87.4% of men and women, respectively, in Marketscan (adjusted relative risk 0.95; 95% CI 0.90-1.01) and 91.5% and 88.1% of men and women, respectively, in Medicare (adjusted relative risk 0.97; 95% CI 0.95-0.99), remained on a high intensity statin following hospital discharge. Conclusions: Women are less likely than men to receive high intensity statins following hospital discharge for MI.
Dose-Dependent Effect of Caffeine on Adenosine-Induced Myocardial Stress Perfusion in Rubidium-82 Positron-Emission Tomography/Computed Tomography
Authors: Christina Byrne, Andreas Kjaer, Mads Wissenberg, Preetee Kapisha Hurry, Anne Schmedes, Julie Lyng Forman, Philip Hasbak
Journal: JACC. Cardiovascular imaging (2019)
AB0593 Predictors of fatigue and severe fatigue in a large multicenter international cohort of patients with systemic lupus erythematosus: the fatilup study
Authors: L. Arnaud, P.-E. Gavand, Z. Amoura, G. Blaison, R. Voll, A. Schwartzing, N. Magy Bertrand, F. Maurier, J.-L. Pennaforte, V. Poindron, P. Kieffer, B. Bonnote, H. Lorenz, C. Fiehn, J. Sibilia, T. Martin
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Fatigue is an important issue in systemic lupus and has a major impact on quality of life of the patients. Data are controversial about the factors associated with this complex symptom.<sup>1</sup> <h3>Objectives</h3> To identify the factors associated with fatigue and severe fatigue in patients with systemic lupus erythematosus (SLE) in a large cohort using a multivariate model to precise the importance of each parameter in this multidimensional symptom. <h3>Methods</h3> We used the LBBR data base, a German French data base of SLE patients. All patients fulfilled the 1997 ACR criteria for SLE. The Fatigue Scale for Motor and Cognitive Functions (FSMC) was used to assess fatigue and severe fatigue. The depression and anxiety were measured with Hospital Anxiety and Depression Scale (HADS). Tests were performed at sampling. <h3>Results</h3> A total of 570 patients were included (89.1% female). The median age was 42 years (QR25–75: 34–52). The median value of the SELENA-SLEDAI was 2 (QR25–75: 0–4) and 136 patients had a SELENA-SLEDAI score &gt;6. Fatigue was reported by 386 patients (67.7%) including severe fatigue by 209 (36.7%). In univariate analysis among the individual components of the SLEDAI arthritis (p=0.003) and oral ulcers (p=0.002) were associated with severe fatigue. In multivariate analysis fatigue was strongly associated with anxiety (OR: 4.49 [95%CI: 2.60–7.77], p&lt;0.0001) and depression (OR: 4.72 [95%CI: 1.39–16.05, p=0.01]. It was also associated with age at sampling (OR: 1.01 [95%CI: 1.00–1.03, p=0.03] per 1 year increase), SLEDAI (OR: 1.05 [95%CI: 1.00–1.12, p=0.043] per 1 SLEDAI point increase) and glucocorticoids treatment (OR: 1.54 [95%CI: 1.00–2.38, p=0.04]). It was not associated with physical activity. Severe fatigue was strongly associated with depression (OR:6.87 [95%CI: 3.12–15.11], p&lt;0.0001) and anxiety (OR: 3.80 [95%CI: 2.46–5.87], p&lt;0.0001) but not with SLEDAI or physical activity. <h3>Conclusions</h3> Fatigue is a common symptom in SLE patients and is strongly associated with anxiety and depression. While remission remains an important therapeutic target, these manifestations should also be taken care of with psychological counselling and pharmacological intervention, when needed. <h3>Reference</h3> [1] Cleanthous S, Tyagi M, Isenberg DA, Newman SP. What do we know about self-reported fatigue in systemic lupus erythematosus?Lupus. 2012Apr;21(5):465–76 <h3>Disclosure of Interest</h3> None declared
OP0221-PARE Know their numbers: what do ra patients know about their own biomedical data?
Authors: T. Ngcozana, A. Bhatia
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Evidence shows that patients with a higher knowledge regarding their health, experience better health and have better outcomes, this leads to lower costs for the National Health Service. The Blood Pressure Association UK encourages the public to know their biomedical data. Similarly, there is a desire for patients with chronic diseases such as rheumatoid arthritis (RA) to know their biomedical data (blood pressure, lipid profile, DAS 28 score, BMI, blood sugar etc). It is well documented that patients with RA are at a high risk of developing cardiovascular disease. <h3>Objectives</h3> The aims of this study were to ascertain the existing knowledge that patients have on their biomedical data, understand the barriers of knowing these health indicators and enquire how their knowledge can be improved. <h3>Methods</h3> 50 consecutive patients with RA seen in a nurse-led clinic were asked to complete an anonymised questionnaire. The questionnaire consisted of 10 questions which assessed demographics, the patients' knowledge of their current biomedical data and the importance of knowing this information. It also enquired if patients knew what the term 'know your numbers' meant, reasons for not knowing and what could be done to increase their knowledge in knowing their numbers. <h3>Results</h3> 80% (n=40) questionnaires were returned. The estimated mean age (mean ±SD, years) was 58.1±13.4. A majority of the respondents were female (87.5%). The highest category of disease duration for the cohort was between 2–5 years with 40% (n=16) patients. 30% (n=12) of the respondents were aware of the 'know your numbers' concept. 27.5% (n=11) knew their cholesterol while 80% did not know their last blood sugar. The majority 90% (n=36) did not know their BMI. Only 25% of the respondents knew their DAS score. 50% knew the significance of the numbers. 40% (n=16) reported that no one had informed them about the numbers. 95% (n=38) of the participants showed interest in knowing their numbers and 27.5% (n=11) suggested that a written record explained and regularly updated would be appropriate whilst 35% (n=14) proposed that a multidisciplinary input would be useful in regularly informing them of the numbers. <h3>Conclusions</h3> Although cardiovascular disease risk assessment and the management has improved in RA. There still remains a gap in patient engagement and activation in taking responsibility in knowing the risks and what they mean. It is well documented that patients with increased level of activation are more likely to engage in positive health behaviours resulting better outcomes. Our study has shown that although patients do not know much about their biomedical data they are interested in knowing about them. Knowing their biomedical may encourage them to take more ownership of their health even leading to more self-managing their RA. <h3>Disclosure of Interest</h3> None declared
AB0035 A physiological network of igg autoantibodies targeting g protein coupled receptors
Authors: O.C. Marques, A. Marques, R. de Vito, L.M. Giil, J. Rademacher, J. Günther, G. Marschner, S. Pitann, S. Adler, D. Dragun, P. Lamprecht, A. Müller, X. Yu, F. Petersen, H. Heidecke, B.E. Engelhardt, G. Riemekasten
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Since the time when Paul Ehrlich conceived the term "horror autotoxicus", autoantibodies have been associated with the development of autoimmune diseases. However, several works have recently shown the presence of autoantibodies in sera from healthy subjects (n=489), who do not develop autoimmune diseases. <h3>Objectives</h3> Here, we report a network of immunoglobulin G (IgG) autoantibodies targeting G protein-coupled receptors (GPCRs), growth factors and growth factor-related molecules in sera from healthy subjects. <h3>Methods</h3> Autoantibody levels in sera were assessed using ELISA. Autoantibody network was analysed by exploratory factor analysis (EFA), dandelion plot method, hierarchical clustering, and multi-study factor analysis (MFA). We also reverse engineered autoantibody functions through <i>in silico</i> evaluation of autoantibody target interactions using STRING and <i>g</i>ene ontology (GO). To test the autoantibodies functionality we assessed the <i>in vitro</i> production of IL-8 by PBMCs and neutrophil migration in response to IgG from healthy subjects as well as ETAR-immunised and control mice. Leukocyte cellularity to secondary immune organs was analysed comparing ETAR-immunised with control mice. <h3>Results</h3> Gender, age and the presence of pathological conditions (systemic sclerosis n=84, Alzheimer's disease n=91 and ovarian cancer n=207) changed correlations between the autoantibodies and their hierarchical clustering distribution. Notably, subjects at age below and above 65 years or with pathological conditions exhibited particular autoantibody hierarchical clustering signatures. In addition, females at age above 65 years, representing the group of subjects with higher risk to develop SSc, displayed the closest link to SSc in terms of autoantibody hierarchical clustering. Finally, autoantibody directed against the endothelin receptor type A (ETAR) showed an essential role in the autoantibody network by orchestrating neutrophil trafficking <i>in vitro</i> and in ETAR-immunised mice. <h3>Conclusions</h3> Our data provide a framework for the existence of a physiological network of autoantibodies and reveal a new paradigmatic view on these physiological molecules. <h3>Disclosure of Interest</h3> None declared
Abstract 18899: Serum Levels of Remnant-like Particle Cholesterol Play a Critical Role in the Pathogenesis of Coronary Spasm
Authors: Noriyuki Wakana, Kan Zen, Shinichiro Motoyama, Masakazu Kikai, Shinichiro Yamaguchi, Takuo Nakagami, Naohiko Nakanishi, Takeshi Nakamura, Satoaki Matoba
Journal: Circulation (2017)

Introduction: High levels of remnant-like particle cholesterol (RLP-C) are considered a coronary risk factor and predictor of cardiovascular events. However, the relationship of RLP-C with coronary spasm (CS) remains unclear. Objective: This study aimed to examine the possible relationship of circulating serum levels of RLP-C with CS. Methods: We retrospectively evaluated 154 consecutive patients who underwent a provocation test on suspicion of a coronary spasm angina. We compared the traditional coronary risk factors and serum levels of RLP-C between patients who had positive and those who had negative provocation test results. We also examined the relationship of serum levels of RLP-C with the grade of coronary spasm caused by the provocation test (grade 0, no coronary spasm caused in any of the branches; grade 1, coronary spasm in one branch; grade 2, coronary spasm in multiple branches). We next compared the receiver-operating characteristic (ROC) curve between the traditional risk factors with or tho...
Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus
Authors: Chris Wincup, Madhvi Menon, Edward Smith, Ann Schwartz, David Isenberg, Elizabeth C Jury, Claudia Mauri
Journal: Annals of the Rheumatic Diseases (2019)

ADA positive N=21 ADA negative N=36 P valueAge at diagnosis, years (SD) 22.0 (7
Corrigendum to “Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B” [J Hepatol 69 (2018) 278–285]
Authors: Yao-Chun Hsu, Terry Cheuk-Fung Yip, Hsiu J. Ho, Vincent Wai-Sun Wong, Yen-Tsung Huang, Hashem B. El-Serag, Teng-Yu Lee, Ming-Shiang Wu, Jaw-Town Lin, Grace Lai-Hung Wong, Chun-Ying Wu
Journal: Journal of Hepatology (2019)
AB0382 Rapamycin selectively increases circulating tregcellsand maintain remission of patients with rheumatoid arthritis
Authors: N. Yan, H. Yao, F. Hu, J. Liang, H. Niu, X. Li, C. Gao, C. Wang
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> It is thought that Rheumatoid arthritis (RA) arises from a breakdown in immunological self-tolerance. We have givena direct evidence for this conceptionthat absolute number of peripheral CD4<sup>+</sup>Regulatory T-cells (Tregs) decreased inRA patients<sup>[1]</sup>. Furthermore, rapamycin can significantly induce immune tolerance through up-regulate Tregs and down-regulate Th17 cells<sup>[2]</sup>. <h3>Objectives</h3> To investigate the effect of rapamycin on the absolute numbers of Th17 and Treg cells and on maintenance of disease remission in RA patients instead of DMARDs. <h3>Methods</h3> Thirty-two patients, who achieved remission(DAS28 ≤2.6) by the treatment with two kinds of DMARDs for more than half a year, received rapamycin at a dose of 0.5 mg every other dayfor 12 weeks. Before and after treatment with rapamycin, thediseaseactivity and immunological assessments of them were performed. In this study, BD Trucount tubes with the lyophilized pellet of a known number of internal counting beads were used for determining absolute counts of total CD4<sup>+</sup> T cells in peripheral blood and then calculating the absolute number of Th17 cells and CD4<sup>+</sup>Tregs. <h3>Results</h3> At week 12, 65.6% of the patients maintained remission (DAS28 ≤2.6). TheDAS28 was increased from a median of 2.03(at week 0) to 2.15(at week 12) (p&gt;0.05). The absolute numberof Treg cells was increased significantly from a median of 22.16(at week 0) to 32.19(at week 12) (P=0.039). The absolute number of Th17 cells was decreased from a median of5.98(at week 0) to 5.56(at week 12) (p&gt;0.05). The ratio of Th17/Treg cells was also decreased from a median of 0.245(at week 0) to 0.19(at week 12) (p&gt;0.05). At the same time, the mean dosage of prednisone decreased from 6.29 mg/d to 5.35 mg/d and thatof DMARDs were also reduced from93.75% to 56.25%. <h3>Conclusions</h3> Rapamycin was effective in the maintenance of remission(DAS28 ≤2.6)by increase of Treg cells and correcting the imbalance of Th17/Treg cells. Meantime, the mean dosage of conventional drugs such as glucocorticoid and DMARDs gradually decreased. In the future, rapamycin may replace current immunosuppressant for treatment of RA. <h3>References</h3> [1] Niu H, Li Z, He J, et al. Rapamycin selectively increases circulating Treg cells and modulates the imbalance of Th17/Treg cells in patients with low active rheumatoid arthritis. [2] Yang X, Yao Q, Hu X, et al. Rapamycin-conditioned dendritic cells induced immune tolerance through the regulation of Treg/Th17 cells in mice. Zhonghua Yi Xue Za Zhi2015Aug 11;95(30):2469–73. <h3>Disclosure of Interest</h3> None declared
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Authors: Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Lionel Uwer, José Hureaux, Florian Guisier, Delphine Carmier, Jeannick Madelaine, Josiane Otto, Valérie Gounant, Patrick Merle, Pierre Mourlanette, Olivier Molinier, Aldo Renault, Audrey Rabeau, Martine Antoine, Marc G. Denis, Sebastien Bommart, Alexandra Langlais, Franck Morin, Pierre-Jean Souquet
Journal: Journal of Thoracic Oncology (2019)
Abstract MP065: Genetic Loci Associated With Plasma Phospholipid Fatty Acids in the De Novo Lipogenesis Pathway: A Meta-analysis of Genome-wide Association Studies From the Charge Consortium
Authors: Jason H Wu, Rozenn N Lemaitre, Toshiko Tanaka, Weihua Guan, Ani Manichaikul, Millennia Foy, Edmond K Kabagambe, David R Jacobs, Stephen S Rich, David S Siscovick, Jennifer A Nettleton, Stefania Bandinelli, Luigi Ferrucci, Myriam Fornage, Michael Y Tsai, Lyn M Steffen, Dariush Mozaffarian
Journal: Circulation (2012)

Background Palmitic acid (16:0), stearic acid (18:0), palmitoleic acid (16:1n-7), and oleic acid (18:1n-9) are major saturated and mono-unsaturated fatty acids that are synthesized via de novo lipogenesis (DNL) or obtained from the diet. Circulating levels of these fatty acids are linked to several diseases including diabetes and heart disease. Prior family and twin studies suggest high heritability of circulating levels, but potential genes involved are unknown. Objective To carry out a Genome-Wide Association Study (GWAS) to investigate genetic determinants of circulating levels of these fatty acids. Methods GWAS in 5 population-based cohorts (n=8,961) of European ancestry. Each study conducted linear regression analysis using an additive genetic model. All analyses were adjusted for age, sex, site of recruitment, and principal components to account for possible population genetic substructure where appropriate. Study-specific results were combined using inverse-variance weighted meta-analysis. Results We found SNPs at 7 novel loci linked at GWA significance to levels of one or more of these fatty acids ( Figure ). Directionality is reported for minor alleles. SNPs in ALG14 were associated with higher levels of 16:0 ( P =2.7x10 -11 ) and lower levels of 18:0 ( P =2.7x10 -11 ). SNPs in FADS1 /2 were associated with higher 18:1n-9 ( P =2.2x10 -32 ) and 16:1n-7 ( P =6.6x10 -13 ), and lower 18:0 ( P =1.3x10 -20 ). SNPs in LPGAT1 were associated with lower 18:0 ( P =2.8x10 -9 ). SNPs in GCKR ( P =9.8x10 -10 ) and HIF1AN ( P =5.7x10 -9 ) were associated with higher 16:1n-7, whereas those in PKD2L1 ( P =5.7x10 -15 ) and another locus on chromosome 2 (not near known genes) were associated with lower 16:1n-7. Conclusion Our findings provide novel evidence that common variations in genes with diverse functions, including protein glycosylation, polyunsaturated fatty acid metabolism, phospholipid modeling, and glucose- and oxygen-sensing pathways, are associated with circulating levels of fatty acids in the DNL pathway.
SAT0064 Cd14+cd16+ monocyte subpopulation is dominant in the inflammation of osteoarthritis synovial fluid
Authors: J. Kim, S.-J. Yoo, Y. Kim, S.W. Kang, S.C. Shim, S.M. Kim
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> In osteoarthritis (OA), the activation of inflammation response involving the interaction of cartilage and synovial hyperplasia may contribute to disease progression. However, inflammatory cells in OA synovial fluid (OASF) have been rarely studied. <h3>Objectives</h3> To investigate the phenotype of CD14 +cells and the secretion of proinflammatory cytokines by these cells <h3>Methods</h3> Immunohistochemistry staining in OA synovium was performed using anti-CD14, anti-CD16 and anti-CD56 antibody. The OASF was obtained through arthrocentesis. Mononuclear cells from OASFs were stained with anti-CD3, anti-CD4, anti-CD14, anti-CD16, anti-TLR4 or anti-TLR2 and analysed using flow cytometry. CD14 +CD16+and CD14+CD16 mononuclar cells in OASF were selected with magnetic microbeads. In the supernatant of these cells culture, the concentration of IL-1β, IL-6, IL-8, TNFα, MMP-1,–3 were measured by Luminex. <h3>Results</h3> In OA synovium, CD14 or CD16 was stained, but CD56 was not expressed. In OASF, there was a substantial number of CD14 +cells (36.6%±25.2%), CD3 +cells (37.4%±12.9%), with a rarity of CD90 +cells (1.7%±1.3%). The proportion of CD14 +cells was increased significantly in recurred synovial fluid, compared with the proportion in initial synovial fluid. Among CD14 +cells in OASF, CD14 +CD16+monocyte subpopulation (21.2%±21.8%) was more abundant than CD14 +CD16− monocyte subpopulation (10.9%±10.0%). TLR4 and TLR2 expressions were higher in CD14 +CD16+cells than in CD14 +CD16− cells. The concentration of IL-8 and MMP-3 was more increased in the supernatant of CD14 +CD16+cells than in that of CD14 +CD16− cells. <h3>Conclusions</h3> In OASF, the proportion of CD14 +cells was increased in recurred synovial effusion. Compared to CD14 +CD16− monocyte subpopulation, CD14 +CD16+monocyte subpopulation released more cytokine such as IL-8 and MMP-3, and had higher expressions of TLR4 and TLR2. <h3>Disclosure of Interest</h3> None declared